Novartis AG’s alliance with the University of Pennsylvania around cancer immunotherapies based on chimeric antigen receptor (CAR) technologies comes at an opportune time for both parties. The Big Pharma needs to reinvigorate its oncology franchise and Penn’s high-profile, albeit much smaller, alliance with AstraZeneca PLC is winding down.
A two-day October conference at Penn’s Institute for Translational Medicine and Therapeutics (ITMAT) featured Carl June, MD, whose work on...